Linked Life Data

1863639

Source:http://linkedlifedata.com/resource/pubmed/id/1863639

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1
pubmed:dateCreated
1991-9-9
pubmed:abstractText
The first three approved human clinical trials utilizing retroviral-mediated gene transfer are now underway. While this technology holds great promise for the study and treatment of human disease, it also poses a number of safety concerns. In evaluating clinical protocols, potential complications and the likelihood of their occurrence are estimated by review committees so that a risk/benefit assessment can be made. Current knowledge, reviewed in this article, suggests that no acute complications secondary to retroviral-mediated gene transfer are likely, but the possibility of long-term or unforeseen sequelae in patients suggests the need for post-treatment monitoring.
pubmed:keyword
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
E
pubmed:status
MEDLINE
pubmed:issn
1043-0342
pubmed:author
pubmed:issnType
Print
pubmed:volume
2
pubmed:geneSymbol
env, gag, myc, pim-1, pol, ras
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
5-14
pubmed:dateRevised
2006-4-21
pubmed:meshHeading
pubmed:year
1991
pubmed:articleTitle
Safety issues related to retroviral-mediated gene transfer in humans.
pubmed:affiliation
Molecular Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892.
pubmed:publicationType
Journal Article, Review